Taking a Look at Patient Experiences In Rectal Cancer Clinical Trials
June 9, 2023 updated by: Power Life Sciences Inc.
Investigating Medical Research Trends in Rectal Cancer Clinical Study: Analyzing Factors Impacting Patient Involvement
The primary objective of this research study is to explore the barriers encountered by specific demographic groups of rectal cancer patients during the engagement in clinical trials, which historically lack diverse representation.
By carefully analyzing data from various demographic perspectives, this study aims to uncover patterns that impact the experiences of future rectal cancer patients. Active involvement in this crucial research is of utmost importance, as it can offer unique insights to enhance the participation and completion rates of rectal cancer patients in clinical study.
Study Overview
Status
Not yet recruiting
Conditions
Study Type
Observational
Enrollment (Estimated)
500
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael B Gill
- Phone Number: 4159004227
- Email: bask@withpower.com
Study Locations
-
-
California
-
San Francisco, California, United States, 94107
- Power Life Sciences
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Probability Sample
Study Population
Patients with rectal cancer who are actively participating in a clinical research, but have not yet completed enrollment and randomization.
Description
Inclusion Criteria:
- Confirmed diagnosis of rectal cancer
- Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
- No prior treatment for rectal cancer
Exclusion Criteria:
- Pregnant or lactating woman
- Inability to provide written informed consent
- Enrolled in another research study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Number of rectal cancer patients who decide to participate in a clinical study
Time Frame: 3 months
|
3 months
|
|
Rate of patients who remain in a rectal cancer clinical study to completion
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Michael B Gill, Power Life Sciences Inc.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Alvarez Sarrado E, Giner Segura F, Batista Domenech A, Garcia-Granero Garcia-Fuster A, Frasson M, Rudenko P, Flor Lorente B, Garcia-Granero Ximenez E. Rectal cancer at the peritoneal reflection. Preoperative MRI accuracy and histophatologic correlation. Prospective study. Cir Esp (Engl Ed). 2022 Aug;100(8):488-495. doi: 10.1016/j.cireng.2022.05.019. Epub 2022 May 18.
- Bregendahl S, Bondeven P, Gronborg TK, Brown G, Laurberg S, Pedersen BG. Training of radiology specialists in local staging of primary rectal cancer on MRI: a prospective intervention study exploring the impact of various educational elements on the interpretive performance. BMJ Open Qual. 2022 Aug;11(3):e001716. doi: 10.1136/bmjoq-2021-001716.
- Qaderi SM, Dickman PW, de Wilt JHW, Verhoeven RHA. Conditional Survival and Cure of Patients With Colon or Rectal Cancer: A Population-Based Study. J Natl Compr Canc Netw. 2020 Sep;18(9):1230-1237. doi: 10.6004/jnccn.2020.7568.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
July 1, 2024
Primary Completion (Estimated)
July 1, 2025
Study Completion (Estimated)
July 1, 2026
Study Registration Dates
First Submitted
June 9, 2023
First Submitted That Met QC Criteria
June 9, 2023
First Posted (Estimated)
June 19, 2023
Study Record Updates
Last Update Posted (Estimated)
June 19, 2023
Last Update Submitted That Met QC Criteria
June 9, 2023
Last Verified
June 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 85996123
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.